

AcoroScan
Addressing a global healthcare priority that results in 6 million deaths annually.
In a fast, non-invasive test, AcoroScan measures the tiny magnetic field generated by the heart to reveal hidden cardiac electrical defects that can lead to fatal ventricular arrhythmias.
Deployable at scale in standard clinical settings, AcoroScan provides clinicians with a powerful new point of care tool to guide those at risk of sudden cardiac death to life-saving treatments.
A new standard for assessing the risk of sudden cardiac death
Implantable cardioverter defibrillators (ICD) are effective at preventing sudden cardiac death, but…
80%
of those fitted with an ICD do not need one
80%
of those who would benefit do not receive one
Leading to 300k avoidable deaths and >$20bn of wasted healthcare spend every year.
Source: Acoro, 2025 and references therein “Scale of aSCD challenge and limitations of current ICD targeting methods” – available on request
Routine adoption of AcoroScan for assessing risk of SCD in cardiac patients could:
Increase access to ICDs and save
35,000
additional lives annually
Reduce ineffective ICD implants and save
$6.4BN
in healthcare costs annually
Source: Acoro, 2025 and references therein “Modelling of clinical and financial impact of introducing AcoroScan MCG aSCD risk stratification to guide ICD implantation” – available on request
SCD risk marker validated in pilot clinical study
Proprietary AcoroScan risk-marker was significantly correlated to a future arrhythmic event.
Offers the potential to reduce ineffective ICD implants by 50% compared to current clinical guidance.
ICD Shock vs Acoro SCD risk score
AUC 0.814 / 0.809
Results from Magneto-SCD trial – publication in progress
Trial protocol: Lachlan T, et al. BMJ Open 2020;10:e038804. doi:10.1136/bmjopen-2020-038804
Point of care assessment for SCD risk
AcoroScan provides an actionable SCD risk score from a 5-minute scan within cardiac care environments.
High patient throughput supports site subscription or fee-per-scan pricing.
Additional Clinical Risk Factors


ACORO
aSCD Risk Score

AcoroScan
aSCD Biomarker
Our Company
Acoro Limited is a medical device spin-out company from Leeds University, UK with a vision to transform care for those at risk of sudden cardiac death.
Following compelling performance from a pilot clinical study, we’re working tirelessly to make routine assessment of electrical heart defects a reality.
Our Core Team

Dr. David Brooks
CEO
30 years experience in device, diagnostic & drug development, fundraising both private & public. Numerous exits including a diagnostic company to KKR.

Dr. Neil Loxley
CHAIR
30 years experience in funding and growth of VC-backed MedTech and technology businesses as CEO, Chairman and NED.

Dr. Simon Webster
NED
25 years of technology development and commercialisation targeting healthcare markets.
Clinical Advisors

Prof. Faizel Osman
CHIEF CLINICAL ADVISOR
Consultant Cardiologist/Electrophysiologist at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust and Honorary Professor of Cardiology at Warwick University medical school.
Research interests in arrhythmia and sudden cardiac death prediction. Principle investigator of the Magneto-SCD trial.

Dr. Tom Lachlan
CLINICAL ADVISOR
Fellow in Cardiology at UHCW NHS Trust.
Trained in Cardiology with speciality training in electrophysiology and devices. Completed PhD demonstrating the predicative ability of room temperature MCG parameters in predicting future ICD shocks.

Dr. Kim Rajappan
CLINICAL ADVISOR
Consultant Cardiologist & Electrophysiologist at John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust.
Specialist in cardiac electrophysiology and treatment of a wide range of conditions associated with heart rhythm